Endometrial Neoplasms
Information
- Disease name
- Endometrial Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05173987 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | February 3, 2022 | May 27, 2027 |
| NCT01820858 | Active, not recruiting | Phase 3 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma | November 2012 | December 2026 |
| NCT01820884 | Active, not recruiting | N/A | The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma | November 2012 | December 2026 |
| NCT04995809 | Active, not recruiting | Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome | June 25, 2021 | December 13, 2024 | |
| NCT05869123 | Active, not recruiting | Phase 1/Phase 2 | Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer | October 20, 2022 | March 3, 2025 |
| NCT04870177 | Active, not recruiting | Phase 2 | Study of AK112 in the Treatment of Advanced Gynecological Tumors | March 16, 2021 | May 2024 |
| NCT04865289 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | October 22, 2019 | January 15, 2025 |
| NCT04634877 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | January 10, 2021 | June 18, 2025 |
| NCT04570839 | Active, not recruiting | Phase 1/Phase 2 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | August 31, 2020 | August 2024 |
| NCT04269200 | Active, not recruiting | Phase 3 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | May 5, 2020 | March 5, 2025 |
| NCT03935282 | Active, not recruiting | N/A | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors | October 1, 2020 | March 7, 2025 |
| NCT03517449 | Active, not recruiting | Phase 3 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | June 11, 2018 | October 7, 2024 |
| NCT05682950 | Active, not recruiting | Phase 2 | Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer | September 12, 2022 | February 2025 |
| NCT03884101 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | April 11, 2019 | January 15, 2025 |
| NCT05588076 | Active, not recruiting | Endometrial Lesions Predictions | October 1, 2021 | December 1, 2022 | |
| NCT02494791 | Active, not recruiting | N/A | Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer | July 2015 | July 2025 |
| NCT03766672 | Active, not recruiting | Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique | November 22, 2019 | November 22, 2024 | |
| NCT02433080 | Completed | N/A | Diet and Physical Activity in Uterine Cancer Survivors | April 2015 | June 2016 |
| NCT04763902 | Completed | N/A | Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer | February 18, 2021 | September 30, 2022 |
| NCT02564276 | Completed | Phase 3 | Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer | February 2016 | July 2017 |
| NCT02676726 | Completed | N/A | STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer | July 2014 | September 8, 2019 |
| NCT02690259 | Completed | N/A | Sentinel Lymph Node Detection in Endometrial Cancer | June 1, 2014 | May 30, 2018 |
| NCT02724501 | Completed | Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer | April 2000 | October 2011 | |
| NCT02725268 | Completed | Phase 2 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | April 1, 2016 | October 30, 2020 |
| NCT02865889 | Completed | Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications | September 2008 | ||
| NCT03207074 | Completed | N/A | Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? | June 13, 2017 | June 1, 2020 |
| NCT03270995 | Completed | N/A | Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study | October 2014 | February 1, 2020 |
| NCT03276013 | Completed | Phase 2 | Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer | May 30, 2018 | August 26, 2021 |
| NCT03917147 | Completed | Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination | January 8, 2018 | December 9, 2018 | |
| NCT00050440 | Completed | Phase 2 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | July 2002 | July 2004 |
| NCT05977829 | Completed | Endometrial Malignancy in Breast Cancer Patients With or Without AUB | January 1, 2020 | July 30, 2022 | |
| NCT00250783 | Completed | Pre-Clinical Models in Gynecological Tumors A Tissue Repository | July 2002 | January 2008 | |
| NCT00288821 | Completed | Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology | February 2006 | March 2009 | |
| NCT00341458 | Completed | Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics | September 1, 1999 | April 16, 2020 | |
| NCT00377520 | Completed | Phase 2 | A Trial for Patients With Advanced/Recurrent Endometrial Cancer | September 2006 | September 2008 |
| NCT05375136 | Completed | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | June 25, 2021 | November 7, 2023 | |
| NCT00987051 | Completed | N/A | Sentinel Node and Endometrial Cancer | April 2007 | October 2011 |
| NCT01013324 | Completed | Phase 2 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | January 2010 | March 2013 |
| NCT01460979 | Completed | Phase 2 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | October 2011 | November 2015 |
| NCT01549782 | Completed | N/A | Mixture of Prebiotics on Intestinal Microbiota of Patients Receiving Abdominal Radiotherapy. | June 2005 | December 2007 |
| NCT01717391 | Completed | Phase 2 | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | October 1, 2012 | April 30, 2017 |
| NCT01810874 | Completed | N/A | STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer | June 2012 | April 2015 |
| NCT01847703 | Completed | N/A | Robotic Versus Abdominal Surgery for Endometrial Cancer | April 2013 | July 2017 |
| NCT04972682 | Completed | N/A | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer | July 1, 2021 | April 15, 2024 |
| NCT02387645 | Completed | N/A | LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma | May 2014 | March 2018 |
| NCT06409039 | Enrolling by invitation | POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation | September 4, 2023 | December 31, 2024 | |
| NCT06363708 | Not yet recruiting | N/A | Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer | June 1, 2024 | June 30, 2026 |
| NCT05974995 | Not yet recruiting | N/A | Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer | September 1, 2023 | September 1, 2029 |
| NCT06023862 | Not yet recruiting | Phase 2 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | January 22, 2024 | December 31, 2029 |
| NCT06126393 | Not yet recruiting | MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer | January 1, 2024 | June 30, 2027 | |
| NCT06171581 | Not yet recruiting | N/A | Effect of Stress Ball Use on Anxiety Level During Endometrial Biopsy Procedure | February 2024 | March 2024 |
| NCT03543215 | Recruiting | Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer? | July 13, 2017 | December 10, 2025 | |
| NCT05793749 | Recruiting | N/A | Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy | April 1, 2023 | July 29, 2026 |
| NCT05795244 | Recruiting | Phase 2 | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | October 31, 2023 | December 2029 |
| NCT02288676 | Recruiting | DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics | January 2014 | October 2026 | |
| NCT05945407 | Recruiting | N/A | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | August 1, 2016 | December 31, 2027 |
| NCT06003231 | Recruiting | Phase 2 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | November 14, 2023 | May 31, 2028 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT06400472 | Recruiting | Phase 1 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | May 6, 2024 | April 2027 |
| NCT05657483 | Recruiting | Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study | December 10, 2022 | December 10, 2024 | |
| NCT04956640 | Recruiting | Phase 1/Phase 2 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | July 19, 2021 | February 2026 |
| NCT06379113 | Recruiting | Phase 2/Phase 3 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | July 13, 2022 | March 30, 2025 |
| NCT04976634 | Recruiting | Phase 2 | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | August 18, 2021 | March 22, 2027 |
| NCT04008797 | Recruiting | Phase 1 | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | July 11, 2019 | March 15, 2027 |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05129969 | Recruiting | Registry Platform Ovarian and Endometrial Cancer | November 25, 2021 | December 2027 | |
| NCT05687084 | Recruiting | N/A | Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial | January 16, 2023 | December 31, 2031 |
| NCT04403867 | Recruiting | The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study. | January 2, 2020 | January 2027 | |
| NCT05194072 | Recruiting | Phase 1 | A Study of SGN-B7H4V in Advanced Solid Tumors | January 12, 2022 | January 31, 2027 |
| NCT05770102 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | October 25, 2023 | October 2029 |
| NCT05316935 | Recruiting | Phase 2/Phase 3 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | July 13, 2022 | March 30, 2025 |
| NCT00936598 | Terminated | N/A | Sleep and Endometrial Cancer | July 2009 | April 2011 |
| NCT04665921 | Terminated | Phase 1 | A Study of SGN-STNV in Advanced Solid Tumors | January 18, 2021 | March 1, 2024 |
| NCT01969396 | Terminated | N/A | Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology | October 2013 | September 2014 |
| NCT01420081 | Terminated | Phase 2 | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer | January 19, 2012 | December 25, 2015 |
| NCT05067972 | Terminated | Phase 1 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | October 7, 2021 | October 17, 2023 |
| NCT05229900 | Terminated | Phase 1 | A Study of SGN-ALPV in Advanced Solid Tumors | April 21, 2022 | December 13, 2023 |
| NCT02900248 | Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice | October 2, 2017 | March 29, 2019 | |
| NCT00178802 | Unknown status | Phase 2 | Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers | June 1996 | December 2010 |
| NCT03570437 | Unknown status | Phase 2 | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | May 17, 2018 | June 30, 2023 |
| NCT03291106 | Unknown status | Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer | September 1, 2017 | October 1, 2020 | |
| NCT03778255 | Unknown status | N/A | Sentinel Lymph Node Mapping In Endometrial Cancer | December 15, 2018 | June 30, 2020 |
| NCT03207126 | Unknown status | N/A | Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? | June 13, 2017 | January 1, 2022 |
| NCT03207061 | Unknown status | N/A | Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? | June 13, 2017 | January 1, 2022 |
| NCT03112733 | Unknown status | Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers | April 4, 2017 | May 30, 2019 | |
| NCT03951415 | Unknown status | Phase 2 | Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer | July 8, 2019 | August 1, 2021 |
| NCT03000192 | Unknown status | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | August 2016 | September 2021 | |
| NCT02512848 | Unknown status | The Feasibility Study of the Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period | April 2015 | July 2022 | |
| NCT04867109 | Unknown status | HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding | June 25, 2021 | September 1, 2022 | |
| NCT01178736 | Unknown status | Early Detection of Cancers in Low Resource Countries | March 2011 | March 2014 | |
| NCT05334303 | Unknown status | The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study | November 17, 2022 | May 1, 2024 | |
| NCT00598845 | Unknown status | Molecular Markers in Treatment in Endometrial Cancer | April 2001 | December 2017 | |
| NCT05634798 | Unknown status | An Observational Study Based on Endometrial Cancer Risk Screening Model | December 1, 2022 | December 1, 2023 | |
| NCT00391664 | Unknown status | Questionnaire Study for Gynecological Cancer Survivors | February 2006 | February 2011 | |
| NCT00299481 | Unknown status | Tissue Bank of Biological Specimens From Patients With Gynecologic Disease | March 2006 | January 2011 | |
| NCT03291275 | Unknown status | Survival Outcomes of Uterine Malignancies in Chinese Population | September 1, 2017 | September 1, 2023 | |
| NCT01888562 | Withdrawn | N/A | Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | January 2016 | July 2023 |
| NCT03005015 | Withdrawn | Phase 2 | Lenvatinib in Second Line Endometrial Carcinoma | January 2017 | |
| NCT00250770 | Withdrawn | Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis | January 1998 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016889